Rapid Point-of-Care RNA Diagnostic for Dengue Infection

登革热感染的快速护理点 RNA 诊断

• 批准号: 10469689
• 负责人: HyunDae Cho
• 金额: $ 99.98万
• 依托单位: CROSSLIFE TECHNOLOGIES, INC.
• 依托单位国家: 美国
• 财政年份: 2019
• 资助国家: 美国
• 起止时间: 2019-03-15 至 2024-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10469689
• 关键词: Achievement; Antibodies; Antigens; Area; Base Sequence; Biological Assay; Biosensor; Blood; Blood Tests; Blood specimen; Borrelia; Brazil; Centers for Disease Control and Prevention (U.S.); Cessation of life; Chikungunya virus; Clinical; Colombia; Containment; Country; Cytomegalovirus; Dangerousness; Data; Data Set; Dengue; Dengue Fever; Dengue Infection; Dengue Virus; Detection; Development; Devices; Diagnostic; Diagnostic tests; Disease; Dissociation; Early Diagnosis; Epidemic; Evaluation; Feedback; Fever; Goals; Health; Herpesvirus 1; Herpesvirus Type 3; Hospitals; Human; Human Resources; Infection; Instruction; Laboratories; Lateral; Latin America; Leptospira; Malaria; Methods; Modification; Molecular; Monitor; Nucleic Acid Amplification Tests; Nucleic Acids; Organism; Outcome Measure; Pan American Health Organization; Panama; Paper; Patients; Performance; Periodicity; Peripheral; Phase; Power Sources; Preparation; Process; Public Health; Publications; Quarantine; RNA; Rapid diagnostics; Reagent; Recommendation; Refrigeration; Reporting; Reproducibility; Resource-limited setting; Resources; Reverse Transcriptase Polymerase Chain Reaction; Rickettsia; Running; Sampling; Sensitivity and Specificity; Singapore; Site; South America; Southeastern Asia; Specificity; Specimen; St. Louis Encephalitis Virus; Supportive care; System; Taiwan; Technology; Testing; Time; Training; Triage; Universities; Validation; Virus; West Nile virus; Whole Blood; World Health Organization; Yellow fever virus; antigen test; commercialization; cost; cross reactivity; design; detection assay; detection limit; detection method; detection test; diagnostic assay; economic impact; expedited review; field study; innovative technologies; instrument; instrumentation; medical schools; mosquito-borne; new technology; pathogen; pathogenic virus; performance tests; point of care; point-of-care diagnostics; public health relevance; rapid detection; rapid test; test strip; viral RNA; waiver

Abstract Rapid Point-of-Care RNA Diagnostic for Dengue Infection CrossLife Technologies Inc. Project Summary/Abstract Dengue viruses (DENV) are one of the most dangerous and significant pathogens in the world, and there are 230 million cases of dengue virus infections per year, mostly in Latin America and Southeast Asia. These mosquito-borne viruses cause periodic explosive epidemics in many tropical and sub-tropical countries. CrossLife technologies' dengue diagnostic is being developed to detect dengue infection early at the point-of-care so that patients can be treated effectively. Early and rapid detection of dengue virus (DENV) infection during the febrile period is crucial for proper patient management and containment of the disease. However, current methods for early detection of dengue involve the use of RT-PCR instruments in the laboratory, which may not be available in areas where dengue is endemic, and which may be too slow. CrossLife Technologies proposed to develop a Template Assisted Rapid Assay (TARA) diagnostics for detection of dengue viruses in human blood. TARA dengue diagnostic will detect dengue in 30 minutes on a paper strip at the point-of-care (POC) so that patients can be treated rapidly and at low cost. This innovative technology will provide PCR-less, instrumentation-free, low-cost, disposable, rapid and sensitive POC dengue diagnostics directly from whole blood samples.

摘要 登革感染的快速护理点RNA诊断CrossLife Technologies Inc.登革病毒（DENV）是世界上最危险和最重要的病原体之一，每年有2. 3亿例登革病毒感染病例，主要发生在拉丁美洲和东南亚。这些蚊媒病毒在许多热带和亚热带国家引起周期性的爆发性流行病。交叉生命技术公司的登革热诊断正在开发中，以检测登革热感染早期在护理点，使病人可以得到有效的治疗。在发热期早期和快速检测登革病毒（DENV）感染对于适当的患者管理和控制疾病至关重要。然而，目前用于早期检测登革热的方法涉及在实验室中使用RT-PCR仪器，这在登革热流行的地区可能无法获得，并且可能太慢。CrossLife Technologies提出开发一种模板辅助快速检测（塔拉）诊断方法，用于检测人体血液中的登革热病毒。塔拉登革热诊断将在30分钟内在护理点（POC）的纸条上检测登革热，以便患者可以快速，低成本地治疗。这项创新技术将直接从全血样本中提供无PCR、无仪器、低成本、一次性、快速和灵敏的POC登革热诊断。